Routine viral load monitoring and enhanced adherence counselling at a public ART centre in Mumbai, India
Authors
Laxmeshwar, CAcharya, S
Das, M
Keskar, P
Pazare, A
Ingole, N
Mehta, P
Gori, P
Mansoor, H
Kalon, S
Singh, P
Mathur, T
Ferlazzo, G
Isaakidis, P
Issue Date
2020-05-05Submitted date
2020-07-09
Metadata
Show full item recordJournal
PloS OneAbstract
Background Routine viral-load (VL) measurements along with enhanced adherence counselling (EAC) are recommended to achieve virological suppression among people living with HIV/AIDS (PLHA) on anti-retroviral therapy (ART). The Mumbai Districts AIDS Control Society along with Médecins Sans Frontières has provided routine VL measurements and EAC to PLHA on ART at King Edward Memorial (KEM) hospital, Mumbai since October-2016. This study aims to describe the initial VL results and impact of EAC on viral suppression and factors associated with initial viral non-suppression among patients with an initial detectable VL, in a cohort of patients tested between October-2016 and September-2018. Methods This is a descriptive study of PLHA on ART who received VL testing and EAC during October-2016 to September-2018. Log-binomial regression was used to identify factors associated with a high VL. Results Among 3849 PLHA who underwent VL testing, 1603(42%) were female and median age was 42 years (IQR:35–48). Majority were referred for routine testing (3432(89%)) and clinical/immunological failure (233(6%)). Overall, 3402(88%) PLHA had suppressed VL at initial testing. Among 3432 tested for routine monitoring, 3141(92%) had VL suppressed. Of 291 with VL>1000c/ml, 253(87%) received EAC and after repeat VL, 70(28%) had VL<1000c/ml. Among 233 referred for clinical/immunological failure, 122(52%) had VL>1000c/ml and 109 have been switched to second-line ART. CD4 count<500 (aOR-5.0[95%CI 3.8–6.5]), on ART for<5 years (aOR-1.5[1.1–2.0]) and age<15 years (aOR-5.2[3.0–8.9]) were associated with an initial VL>1000c/ml. Factors associated with follow-up VL suppression included EAC (p<0.05) and being on second-line ART (p<0.05). Conclusion Results from a routine VL program in public sector in India were encouraging and in line with UNAIDS 90-90-90 targets. Routine VL monitoring along with EAC resulted in early switch to alternative optimised regimens while also preventing unnecessary switches. Along with the vital scale up of routine VL monitoring, implementation of enhanced adherence strategies for patients with detectable viral load should be ensured.Publisher
Public Library of SciencePubMed ID
32369504Type
ArticleLanguage
enEISSN
1932-6203ae974a485f413a2113503eed53cd6c53
10.1371/journal.pone.0232576
Scopus Count
Collections
Related articles
- Successes and challenges in optimizing the viral load cascade to improve antiretroviral therapy adherence and rationalize second-line switches in Swaziland.
- Authors: Etoori D, Ciglenecki I, Ndlangamandla M, Edwards CG, Jobanputra K, Pasipamire M, Maphalala G, Yang C, Zabsonre I, Kabore SM, Goiri J, Teck R, Kerschberger B
- Issue date: 2018 Oct
- Second-line failure and first experience with third-line antiretroviral therapy in Mumbai, India.
- Authors: Khan S, Das M, Andries A, Deshpande A, Mansoor H, Saranchuk P, Isaakidis P
- Issue date: 2014
- When patients fail UNAIDS' last 90 - the "failure cascade" beyond 90-90-90 in rural Lesotho, Southern Africa: a <i>prospective cohort study</i>.
- Authors: Labhardt ND, Ringera I, Lejone TI, Cheleboi M, Wagner S, Muhairwe J, Klimkait T
- Issue date: 2017 Jul 19
- Genotyping and outcomes of presumptive second line ART failure cases switched to third line or maintained on second line ART in Mumbai, India.
- Authors: Gill N, Van den Bergh R, Wut Yee Kyaw K, Laxmeshwar C, Das M, Rastogi S, Arago Galindo M, Mansoor H, Kalon S, Isaakidis P
- Issue date: 2019
- Adoption of routine virologic testing and predictors of virologic failure among HIV-infected children on antiretroviral treatment in western Kenya.
- Authors: Kadima J, Patterson E, Mburu M, Blat C, Nyanduko M, Bukusi EA, Cohen C, Oyaro P, Abuogi L
- Issue date: 2018